Amyloid endostatin induces endothelial cell detachment by stimulation of the plasminogen activation system

Molecular Cancer Research

Volumn 1, Issue 8, 2003, Pages 561-568

  Reijerkerk, Arie ^a   Mosnier, Laurent O ^a   Kranenburg, Onno ^a   Bouma, Bonno N ^a   Carmeliet, Peter ^b   Drixler, Tom ^a   Meijers, Joost C M ^a,c   Voest, Emile E ^a   Gebbink, Martijn F B G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; CARBOXYPEPTIDASE B; COLLAGEN; COLLAGEN TYPE 18; ENDOSTATIN; LYSINE; PLASMIN; PLASMINOGEN; UNCLASSIFIED DRUG; VITRONECTIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; ENDOTHELIUM CELL; FIBRINOLYSIS; MALE; MOUSE; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STRUCTURE; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; CARBOXYPEPTIDASE B; CATTLE; CELLS, CULTURED; COLONIC NEOPLASMS; ENDOSTATINS; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PLASMIN; PLASMINOGEN; PULMONARY ARTERY; TISSUE PLASMINOGEN ACTIVATOR;

ANIMALIA;

EID: 0037777699     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 390: 404-407, 1997.
2. Ryan, D. P., Penson, R. T., Ahmed, S., Chabner, B. A., and Lynch, T. J., Jr. Reality testing in cancer treatment: the phase I trial of endostatin. Oncologist, 4: 501-508, 1999.
3. Herbst, R. S., Hess, K. R., Tran, H. T., Tseng, J. E., Mullani, N. A., Charnsangavej, C., Madden, T., Davis, D. W., McConkey, D. J., O'Reilly, M. S., Ellis, L. M., Pluda, J., Hong, W. K., and Abbruzzese, J. L. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol., 20: 3792-3803, 2002.
4. Felbor, U., Dreier, L., Bryant, R. A., Ploegh, H. L., Olsen, B. R., and Mothes, W. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J., 19: 1187-1194, 2000.
5. Lin, H. C., Chang, J. H., Jain, S., Gabison, E. E., Kure, T., Kato, T., Fukai, N., and Azar, D. T. Matrilysin cleavage of corneal collagen type -+XVIII NC1 domain and generation of a 28-kDa fragment. Invest. Ophthalmol. Vis. Sci., 42: 2517-2524, 2001.
6. Wen, W., Moses, M. A., Wiederschain, D., Arbiser, J. L., and Folkman, J. The generation of endostatin is mediated by elastase. Cancer Res., 59: 6052-6056, 1999.
7. Sim, B. K., MacDonald, N. J., and Gubish, E. R. Angiostatin and endostatin: endogenous inhibitors of tumor growth. Cancer Metastasis Rev., 19: 181-190, 2000.
8. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.
9. Perletti, G., Concari, P., Giardini, R., Marras, E., Piccinini, F., Folkman, J., and Chen, L. Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors. Cancer Res., 60: 1793-1796, 2000.
10. Chen, Q. R., Kumar, D., Stass, S. A., and Mixson, A. J. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res., 59: 3308-3312, 1999.
11. Feldman, A. L., Restifo, N. P., Alexander, H. R., Bartlett, D. L., Hwu, P., Seth, P., and Libutti, S. K. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res., 60: 1503-1506, 2000.
12. Steele, F. R. Can "negative" be positive? Mol. Ther., 5: 338-339, 2002.
13. Eisterer, W., Jiang, X., Bachelot, T., Pawliuk, R., Abramovich, C., Leboulch, P., Hogge, D., and Eaves, C. Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia. Mol. Ther., 5: 352-359, 2002.
14. Pawliuk, R., Bachelot, T., Zurkiya, O., Eriksson, A., Cao, Y., and Leboulch, P. Continuous intravascular secretion of endostatin in mice from transduced hematopoietic stem cells. Mol. Ther., 5: 345-351, 2002.
15. Jouanneau, E., Alberti, L., Nejjari, M., Treilleux, I., Vilgrain, I., Duc, A., Combaret, V., Favrot, M., Leboulch, P., and Bachelot, T. Lack of antitumor activity of recombinant endostatin in a human neuroblastoma xenograft model. J. Neuro-oncol., 51: 11-18, 2001.
16. Marshall, E. Cancer therapy. Setbacks for endostatin. Science, 295: 2198-2199, 2002.
17. Kim, Y. M., Hwang, S., Kim, Y. M., Pyun, B. J., Kim, T. Y., Lee, S. T., Gho, Y. S., and Kwon, Y. G. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J. Biol. Chem., 277: 27872-27879, 2002.
18. Dhanabal, M., Ramchandran, R., Waterman, M. J., Lu, H., Knebelmann, B., Segal, M., and Sukhatme, V. P. Endostatin induces endothelial cell apoptosis. J. Biol. Chem., 274: 11721-11726, 1999.
19. MacDonald, N. J., Shivers, W. Y., Narum, D. L., Plum, S. M., Wingard, J. N., Fuhrmann, S. R., Liang, H., Holland-Linn, J., Chen, D. H., and Sim, B. K. Endostatin binds tropomyosin. A potential modulator of the antitumor activity of endostatin. J. Biol. Chem., 276: 25190-25196, 2001.
20. Furumatsu, T., Yamaguchi, N., Nishida, K., Kawai, A., Kunisada, T., Namba, M., Inoue, H., and Ninomiya, Y. Endostatin inhibits adhesion of endothelial cells to collagen I via α(2)β(1) integrin, a possible cause of prevention of chondrosarcoma growth. J. Biochem. (Tokyo), 131: 619-626, 2002.
21. Rehn, M., Veikkola, T., Kukk-Valdre, E., Nakamura, H., Ilmonen, M., Lombardo, C., Pihlajaniemi, T., Alitalo, K., and Vuori, K. Interaction of endostatin with integrins implicated in angiogenesis. Proc. Natl. Acad. Sci. USA, 98: 1024-1029, 2001.
22. Kim, Y. M., Jang, J. W., Lee, O. H., Yeon, J., Choi, E. Y., Kim, K. W., Lee, S. T., and Kwon, Y. G. Endostatin inhibits endotheliat and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res., 60: 5410-5413, 2000.
23. Lee, S. J., Jang, J. W., Kim, Y. M., Lee, H. I., Jeon, J. Y., Kwon, Y. G., and Lee, S. T. Endostatin binds to the catalytic domain of matrix metalloproteinase-2. FEBS Lett., 519: 147-152, 2002.
24. Wickstrom, S. A., Veikkola, T., Rehn, M, Pihlajaniemi, T., Alitalo, K., and Keski-Oja, J. Endostatin-induced modulation of plasminogen activation with concomitant loss of focal adhesions and actin stress fibers in cultured human endothelial cells. Cancer Res., 61: 6511-6516, 2001.
25. Hohenester, E., Sasaki, T., Olsen, B. R., and Timpl, R. Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution. EMBO J., 17: 1656-1664, 1998.
26. Ding, Y. H., Javaherian, K., Lo, K. M., Chopra, R., Boehm, T., Lanciotti, J., Harris, B. A., Li, Y., Shapiro, R., Hohenester, E., Timpl, R., Folkman, J., and Wiley, D. C. Zinc-dependent dimers observed in crystals of human endostatin. Proc. Natl. Acad. Sci. USA, 95: 10443-10448, 1998.
27. Kranenburg, O., Bouma, B., Kroon-Batenburg, L. M., Reijerkerk, A., Wu, Y. P., Voest, E. E., and Gebbink, M. F. Tissue-type plasminogen activator is a multiligand cross-β structure receptor. Curr. Biol., 12: 1833-1839, 2002.
28. Kranenburg, O., Kroon-Batenburg, L. M., Reijerkerk, A., Wu, Y. P., Voest, E. E., and Gebbink, M. F. Recombinant endostatin forms amyloid fibrils that bind and are cytotoxic to murine neuroblastoma cells in vitro. FEBS Lett., 539: 149-155, 2003.
29. Fleury, V. and Angles-Cano, E. Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. Biochemistry, 30: 7630-7638, 1991.
30. Ge, M., Tang, G., Ryan, T. J., and Malik, A. B. Fibrinogen degradation product fragment D induces endothelial cell detachment by activation of cell-mediated fibrinolysis. J. Clin. Invest., 90: 2508-2516, 1992.
31. Reinartz, J., Schafer, B., Batrla, R., Klein, C. E., and Kramer, M. D. Plasmin abrogates α v β 5-mediated adhesion of a human keratinocyte cell line (HaCaT) to vitronectin. Exp. Cell Res., 220: 274-282, 1995.
32. Sugimura, M., Kobayashi, H., and Terao, T. Plasmin modulators, aprotinin and anti-catalytic plasmin antibody, efficiently inhibit destruction of bovine vascular endothelial cells by choriocarcinoma cells. Gynecol. Oncol., 52: 337-346, 1994.
33. Davis, G. E., Pintar Allen, K. A., Salazar, R., and Maxwell, S. A. Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. J. Cell Sci., 114: 917-930, 2001.
34. Chain, D., Kreizman, T., Shapira, H., and Shaltiel, S. Plasmin cleavage of vitronectin. Identification of the site and consequent attenuation in binding plasminogen activator inhibitor-1. FEBS Lett., 285: 251-256, 1991.
35. Duffy, M. J. Plasminogen activators and cancer. Blood Coagul. Fibrinolysis, 1: 681-687, 1990.
36. Kramer, M. D., Reinartz, J., Brunner, G., and Schirrmacher, V. Plasmin in pericellular proteolysis and cellular invasion. Invasion Metastasis, 14: 210-222, 1994.
37. Pintucci, G., Bikfalvi, A., Klein, S., and Rifkin, D. B. Angiogenesis and the fibrinolytic system. Semin. Thromb. Hemost., 22: 517-524, 1996.
38. Bell, W. R. The fibrinolytic system in neoplasia. Semin. Thromb. Hemost., 22: 459-478, 1996.
39. Eliceiri, B. P. and Cheresh, D. A. The role of αv integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J. Clin. Invest., 103: 1227-1230, 1999.
40. Dano, K., Andreasen, P. A., Grondahl-Hansen, J., Kristensen, P., Nielsen, L. S., and Skriver, L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res., 44: 139-266, 1985.
41. Odekon, L. E., Blasi, F., and Rifkin, D. B. Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-β to TGF-β. J. Cell. Physiol., 158: 398-407, 1994.
42. Gately, S., Twardowski, P., Stack, M. S., Cundiff, D. L., Grella, D., Castellino, F. J., Enghild, J., Kwaan, H. C., Lee, F., Kramer, R. A., Volpert, O., Bouck, N., and Soff, G. A. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc. Natl. Acad. Sci. USA, 94: 10868-10872, 1997.
43. De Petro, G., Tavian, D., Copeta, A., Portolani, N., Giulini, S. M., and Barlati, S. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. Cancer Res., 58: 2234-2239, 1998.
44. Lindgren, M., Johansson, M., Sandstrom, J., Jonsson, Y., Bergenheim, A. T., and Henriksson, R. VEGF and tPA co-expressed in malignant glioma. Acta Oncol., 36: 615-618, 1997.
45. Hackel, C., Czerniak, B., Ayala, A. G., Radig, K., and Roessner, A. Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma. Cancer, 79: 53-58, 1997.
46. Gris, J. C., Schved, J. F., Marty-Double, C., Mauboussin, J. M., and Balmes, P. Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas. Chest, 104: 8-13, 1993.
47. Yamashita, J., Inada, K., Yamashita, S., Nakashima, Y., Matsuo, S., and Ogawa, M. Tissue-type plasminogen activator is involved in skeletal metastasis from human breast cancer. Int. J. Clin. Lab. Res., 21: 227-230, 1992.
48. Pepper, M. S., Ferrara, N., Orci, L., and Montesano, R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem. Biophys. Res. Commun., 181: 902-906, 1991.
49. Isik, F. F., Gibran, N. S., Jang, Y. C., Sandell, L., and Schwartz, S. M. Vitronectin decreases microvascular endothelial cell apoptosis. J. Cell. Physiol., 175: 149-155, 1998.
50. O'Reilly, M. S., Pirie-Shepherd, S., Lane, W. S., and Folkman, J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science, 285: 1926-1928, 1999.
51. Machovich, R. and Owen, W. G. Denatured proteins as cofactors for plasminogen activation. Arch. Biochem. Biophys., 344: 343-349, 1997.
52. Rhim, T. Y., Park, C. S., Kim, E., and Kim, S. S. Human prothrombin fragment 1 and 2 inhibit bFGF-induced BCE cell growth. Biochem. Biophys. Res. Commun., 252: 513-516, 1998.
53. Machovich, R., Komorowicz, E., Kolev, K., and Owen, W. G. Facilitation of plasminogen activation by denatured prothrombin. Thromb. Res., 94: 389-394, 1999.
54. Volpert, O. V., Lawler, J., and Bouck, N. P. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc. Natl. Acad. Sci. USA, 95: 6343-6348, 1998.
55. Silverstein, R. L., Leung, L. L., Harpel, P. C., and Nachman, R. L. Complex formation of platelet thrombospondin with plasminogen. Modulation of activation by tissue activator. J. Clin. Invest., 74: 1625-1633, 1984.
56. Silverstein, R. L., Nachman, R. L., Leung, L. L., and Harpel, P. C. Activation of immobilized plasminogen by tissue activator. Multimolecular complex formation. J. Biol. Chem., 260: 10346-10352, 1985.
57. Silverstein, R. L., Harpel, P. C., and Nachman, R. L. Tissue plasminogen activator and urokinase enhance the binding of plasminogen to thrombospondin. J. Biol. Chem., 261: 9959-9965, 1986.
58. Zou, Z., Anisowicz, A., Hendrix, M. J., Thor, A., Neveu, M., Sheng, S., Rafidi, K., Seftor, E., and Sager, R. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science, 263: 526-529, 1994.
59. Sheng, S., Truong, B., Fredrickson, D., Wu, R., Pardee, A. B., and Sager, R. Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin. Proc. Natl. Acad. Sci. USA, 95: 499-504, 1998.
60. Huttunen, H. J., Fages, C., Kuja-Panula, J., Ridley, A. J., and Rauvala, H. Receptor for advanced glycation end products-binding COOH-terminal motif of Amphoterin inhibits invasive migration and metastasis. Cancer Res., 62: 4805-4811, 2002.
61. Parkkinen, J. and Rauvala, H. Interactions of plasminogen and tissue plasminogen activator (t-PA) with amphoterin. Enhancement of t-PA-catalyzed plasminogen activation by amphoterin. J. Biol. Chem., 266: 16730-16735, 1991.
62. de Witte, J. H., Sweep, C. G., Klijn, J. G., Grebenschikov, N., Peters, H. A., Look, M. P., van Tienoven, T. H., Heuvel, J. J., Bolt-De Vries, J., Benraad, T. J., and Foekens, J. A. Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer. Br. J. Cancer, 80: 286-294, 1999.
63. Grebenschikov, N., Geurts-Moespot, A., De Witte, H., Heuvel, J., Leake, R., Sweep, F., and Benraad, T. A sensitive and robust assay for urokinase and tissuetype plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols. Int. J. Biol. Markers, 12: 6-14, 1997.
64. Kim, S. J., Shiba, E., Kobayashi, T., Yayoi, E., Furukawa, J., Takatsuka, Y., Shin, E., Koyama, H., Inaji, H., and Takai, S. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. Clin. Cancer Res., 4: 177-182, 1998.
65. Bajzar, L., Manuel, R., and Nesheim, M. E. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J. Biol. Chem., 270: 14477-14484, 1995.
66. Stewart, R. J., Fredenburgh, J. C., Rischke, J. A., Bajzar, L., and Weitz, J. I. Thrombin-activable fibrinolysis inhibitor attenuates (DD)E-mediated stimulation of plasminogen activation by reducing the affinity of (DD)E for tissue plasminogen activator. A potential mechanism for enhancing the fibrin specificity of tissue plasminogen activator. J. Biol. Chem., 275: 36612-36620, 2000.
67. Bajou, K., Noel, A., Gerard, R. D., Masson, V., Brunner, N., Holst-Hansen, C., Skobe, M., Fusenig, N. E., Carmeliet, P., Collen, D., and Foidart, J. M. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med., 4: 923-928, 1998.
68. Bajou, K., Masson, V., Gerard, R. D., Schmitt, P. M., Albert, V., Praus, M., Lund, L. R., Frandsen, T. L., Brunner, N., Dano, K., Fusenig, N. E., Weidle, U., Carmeliet, G., Loskutoff, D., Collen, D., Carmeliet, P., Foidart, J. M., and Noel, A. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J. Cell Biol., 152: 777-784, 2001.
69. Silverman, P., Goldsmith, G. H., Jr., Spitzer, T. R., Rehmus, E. H., and Berger, N. A. Effect of tumor necrosis factor on the human fibrinolytic system. J. Clin. Oncol., 8: 468-475, 1990.
70. Merryman, P., Tannenbaum, S. H., Gralnick, H. R., Yu, K., Arnold, W. S., Alexander, H. R., Fraker, D., and Home, M. K., III. Fibrinolytic and coagulant responses to regional limb perfusions of tumor necrosis factor, interferon-γ, and/or melphalan. Thromb. Haemost., 77: 53-56, 1997.
71. Reijerkerk, A., Voest, E. E., and Gebbink, M. F. No grip, no growth: the conceptual basis of excessive proteolysis in the treatment of cancer. Eur. J. Cancer, 36: 1695-1705, 2000.
72. Deutsch, D. G. and Mertz, E. T. Plasminogen: purification from human plasma by affinity chromatography. Science, 170: 1095-1096, 1970.